CEO Friedhelm Blobel notes that although H1 revenue performance was "disappointing," the Zadaxin channel inventory build-up responsible for sluggish sales growth has been "resolved."
FY13 guidance: Zadaxin sales should "rebound" in H2, growing 50% versus H1. FY13 revenues are seen at $135-145M. Full year adjusted EPS should come in between $0.55-0.61.
The company also says it will file its previously delayed Q1 10-Q "on or around" August 9 after consulting with the SEC. (PR)